SP Tulsian upbeat on Glenmark Pharma, Wockhardt

SP Tulsian of sptulsian.com is upbeat on Glenmark Pharma, Wockhardt and Lupin.

Tulsian told CNBC-TV18, “It is very difficult to take a call on the mid cap or may be the small cap pharma stocks because you have the news flow – take for instance Plethico Pharma. In spite of having company posted an earning per share (EPS) of about Rs 50-55 for the nine months the stock has corrected because of this margin pressure and all that and in spite of the high promoter stake it has corrected from Rs 350 to about Rs 125 and now it has been hitting upper circuit.” He further added, “Take the case of Parenteral Drugs who have sold their Goa unit to Fresenius Kabi and stock seems to be in the limelight. So, it is better to focus on the larger stocks and I will rather be comfortable going for the stocks like Glenmark pharma or may be stocks like Wockhardt, Lupin or may be even Ranbaxy which seems to have settled after having seen a good weakness in the stock having taken place in last one month or so.”